But the FDA now says that a common long-used ingredient ... Hatton, thanks so much for joining the "News Hour." I know you and a co-researcher have been looking at this issue for years.
ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today ...
Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy ... in the blood and extend its half-life. On a conference call, Axsome chief executive Herriot Tabuteau ...